Get the Daily Brief
Latest Biotech News
OraSure submits 30‑minute CT/NG rapid test to FDA: at‑home collection also filed
OraSure Technologies submitted a 510(k) application to the FDA for a rapid, disposable test for Chlamydia trachomatis and Neisseria gonorrhoeae that uses Sherlock Biosciences technology to deliver...
Comanche raises $40M to fund preeclampsia siRNA into first human trials
Comanche Biopharma secured an additional $40 million to advance an siRNA injectable program aimed at treating preeclampsia—the company says the funding will enable initiation of human trials...
Zenas' Phase 3 hits primary endpoint – stock halves after rival comparison
Zenas BioPharma reported that obexelimab met the primary endpoint in its Phase 3 Indigo study for IgG4-related disease, but the topline 56% reduction in flare risk compared unfavorably to Amgen’s...
Sanofi doubles down on Earendil – $160M near‑term pact could reach $2.56B
Sanofi agreed to a new collaboration with AI-driven biologics developer Earendil Labs that provides roughly $160 million in upfront and near‑term payments and carries potential downstream value...
Salus wins NMPA nod – rapid clinical sequencer cleared for China use
Salus Biomed obtained Category III medical device registration from China’s NMPA for its Saluseq Nimbo sequencer, clearing the platform for clinical applications nationwide. The Saluseq Nimbo uses...
OraSure seeks FDA 510(k) for 30‑minute CT/NG self‑test and urine kit
OraSure Technologies submitted a 510(k) to the FDA for a rapid, disposable self‑test for chlamydia and gonorrhea built on Sherlock Biosciences’ technology, along with a Colli‑Pee at‑home urine...
Cas3 genome editing slashes TTR in vivo – long deletions, lower off‑targets
Researchers applying CRISPR–Cas3 achieved substantial targeted deletions at the TTR locus and robust reductions in circulating transthyretin in mouse models. A single lipid‑nanoparticle delivery...
Aktis targets Nasdaq raise up to $209M – funds miniprotein radiopharma trials
Aktis Oncology filed to go public in the U.S., aiming to raise roughly $181.7 million at a $16–$18 per‑share range with an option that could lift proceeds to about $209.6 million. The company...
AbbVie pays $100M upfront to option Zejing’s DLL3 trispecific
AbbVie signed an option‑to‑license agreement with Zejing Biopharmaceutical for alveltamig (ZG006), a trispecific T‑cell engager targeting DLL3. AbbVie will pay $100 million upfront for global...
Servier taps Insilico’s AI platform — multiyear oncology pact worth up to near‑term millions
Servier entered a multiyear research and development collaboration with Insilico Medicine to leverage the Pharma.AI platform for oncology target discovery and early development. Insilico will...
Comanche secures $40M to advance first‑in‑class preeclampsia siRNA into clinic
Comanche Biopharma raised an additional $40 million to fund human testing of its investigational siRNA injectable for preeclampsia, aiming to move the program into multiple clinical sites. The...
Psithera spins out of Roivant with $47.5M — targets immune and inflammatory diseases
Psithera Inc., formerly Psivant Therapeutics, completed a spin‑out from Roivant and announced a $47.5 million Series A to fund immune and inflammatory disease programs. The Watertown, Mass....
Cas3 deletes mutant TTR in vivo — new off-target assay tightens safety
Researchers demonstrated CRISPR–Cas3 can generate long-range deletions at the TTR locus and substantially lower circulating transthyretin in mice, offering an alternative to Cas9 strategies for...
Inhalable exosomes deliver bispecific T‑cell activator — fights ICI‑resistant melanoma
An engineered inhalable exosome platform delivered a bispecific T‑cell activator to pembrolizumab‑resistant metastatic melanoma in preclinical models, reactivating tumor‑infiltrating T cells and...
CONCORD unifies single‑cell landscapes across studies
A new contrastive learning framework, CONCORD, produced denoised, batch‑integrated cell representations that preserve differentiation trajectories and other biological structures across diverse...
SPLISOSM pins down isoforms in space — new spatial transcriptomics tool
Researchers published SPLISOSM, a method to map isoform usage and regulatory mechanisms from spatial transcriptomics data. The tool increases statistical power to detect differential isoform...
AI and experiments resolve RNA structure — integrated toolkit published
A Nature Biotechnology perspective and accompanying work outlined integrated experimental and AI workflows for RNA structure determination, combining high‑throughput chemical probing with machine...
AbbVie pays $100M upfront for Zejing DLL3 candidate — deal could top $1.07B
AbbVie signed an option‑to‑license agreement with Zejing Biopharmaceutical for alveltamig (ZG006), a trispecific T‑cell engager targeting DLL3; AbbVie paid $100 million upfront and could pay an...
Comanche raises $40M to push preeclampsia siRNA into human trials
Comanche Biopharma secured $40 million in new capital to advance its experimental siRNA injectable intended as the potential first therapy for preeclampsia into human testing. The funding will...
Big pharma doubles down on AI discovery: Sanofi and Servier deals land
Sanofi agreed a collaboration with AI biotech Earendil Labs worth $160 million upfront and near‑term to discover multiple bispecific autoimmune programs, with potential milestones lifting the deal...